Jul 7, 2026 07:30AM
Jul 7, 2026 07:30AM
May 14, 2026 08:00AM
Apr 22, 2026 09:23AM
Apr 16, 2026 07:10AM
Apr 16, 2026 07:10AM
Feb 17, 2026 08:30AM Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
Aug 14, 2025 08:00AM
Oct 9, 2023 08:54AM
Aug 11, 2021 08:00AM
Aug 11, 2021 08:00AM
Nov 19, 2020 09:26AM
Nov 18, 2020 05:42PM
Oct 28, 2020 04:30PM MeiraGTx Announces Data from Ongoing Clinical Trial of AAV-RPGR for the Treatment of X-Linked Retinitis Pigmentosa to be Presented at AAO 2020 Virtual Meeting
Oct 28, 2020 04:30PM
Oct 5, 2020 05:58AM
Oct 3, 2020 10:50AM
Oct 3, 2020 10:50AM
Sep 22, 2020 08:32AM
Sep 22, 2020 08:30AM
Sep 22, 2020 08:30AM MeiraGTx Announces Data from Ongoing Clinical Trial of AAV-RPGR for the Treatment of X-Linked Retinitis Pigmentosa to be Presented at EURETINA 2020 Virtual Meeting
Aug 6, 2020 08:00AM
Aug 6, 2020 08:00AM
Aug 5, 2020 08:34AM
Aug 5, 2020 08:30AM
Aug 5, 2020 08:30AM
Jul 17, 2020 07:33AM
Jul 17, 2020 07:30AM MeiraGTx Announces Positive Clinical Data Demonstrating Treatment with AAV-RPGR Investigational Gene Therapy Improves Vision in X-Linked Retinitis Pigmentosa Patients  
Jul 17, 2020 07:30AM
May 7, 2020 04:30PM
May 7, 2020 04:30PM
Mar 11, 2020 05:00PM
Mar 11, 2020 05:00PM
Mar 2, 2020 08:32AM
Mar 2, 2020 08:30AM MeiraGTx Announces Priority Medicines (PRIME) and Advanced Therapy Medicinal Product (ATMP) Designations Granted by the European Medicines Agency to AAV-RPGR Gene Therapy for the Treatment of X-Linked
Mar 2, 2020 08:30AM
Dec 5, 2019 04:30PM
Dec 5, 2019 04:30PM
Nov 7, 2019 08:00AM
Nov 7, 2019 08:00AM
Sep 10, 2019 08:32AM
Sep 10, 2019 08:30AM MeiraGTx To Present Clinical Data from Phase 1/2 Trial of AAV-RPE65 at Upcoming Scientific Conferences
Sep 10, 2019 08:30AM
Aug 8, 2019 07:23AM
Aug 8, 2019 06:50AM
Aug 8, 2019 06:50AM
Aug 7, 2019 04:13PM
Aug 7, 2019 04:12PM
Aug 7, 2019 04:12PM MeiraGTx Announces Proposed Public Offering of Ordinary Shares
Aug 7, 2019 08:00AM

1,171,060 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All